keyword
MENU ▼
Read by QxMD icon Read
search

fish for breast disease

keyword
https://www.readbyqxmd.com/read/28521178/impact-of-2013-asco-cap-guidelines-on-her2-determination-of-invasive-breast-cancer-a-single-institution-experience-using-frontline-dual-color-fish
#1
M Ragazzi, A Bisagni, E Gasparini, E Kuhn, C Bassano, I Tamagnini, M Foroni, M Bortesi, G Falco, G Ferrari, L Braglia, L Savoldi, A Bologna, R Di Cicilia, G Bisagni, G Gardini
PURPOSE: The new ASCO/CAP guidelines published in 2013 (AC2013) significantly modified the scoring criteria for HER2-FISH, introducing the most controversial change to the HER2-equivocal category. We retrospectively evaluated the impact of AC2013 in a cohort of consecutive invasive breast cancers (IBCs) analyzed with frontline dual-color FISH. METHODS: 2788 consecutive IBCs were reclassified based on the AC2013 guidelines. Clinico-pathological features of equivocal IBCs were compared with HER2-negative and HER2-positive IBCs...
May 15, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28447240/relationship-between-ihc4-score-and-response-to-neo-adjuvant-chemotherapy-in-estrogen-receptor-positive-breast-cancer
#2
A Sheri, I E Smith, M Hills, R L Jones, S R Johnston, M Dowsett
AIMS: To determine whether IHC4 score assessed on pre-treatment core biopsies (i) predicts response to neo-adjuvant chemotherapy in ER-positive (ER+) breast cancer; (ii) provides more predictive information than Ki67 alone. METHODS: 113 patients with ER+ primary breast cancer treated with neo-adjuvant chemotherapy at the Royal Marsden Hospital between 2002 and 2010 were included in the study. Pathologic assessment of the excision specimen was made for residual disease...
April 26, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28446533/prognostic-evaluation-of-epidermal-growth-factor-receptor-egfr-genotype-and-phenotype-parameters-in-triple-negative-breast-cancers
#3
Sofia Levva, Vassiliki Kotoula, Ioannis Kostopoulos, Kyriaki Manousou, Christos Papadimitriou, Kyriaki Papadopoulou, Sotiris Lakis, Kyriakos Koukoulias, Vasilios Karavasilis, George Pentheroudakis, Eufemia Balassi, Flora Zagouri, Ioannis G Kaklamanos, Dimitrios Pectasides, Evangelia Razis, Gerasimos Aravantinos, Pavlos Papakostas, Dimitrios Bafaloukos, Grigorios Rallis, Helen Gogas, George Fountzilas
BACKGROUND: Epidermal growth factor receptor (EGFR) aberrations have been implicated in the pathogenesis of triple-negative breast cancer (TNBC) but their impact on prognosis and, therefore, druggability, remain controversial. Herein, we studied EGFR aberrations at different molecular levels and assessed their prognostic impact in patients with operable TNBC treated with adjuvant anthracycline-based chemotherapy. MATERIALS AND METHODS: We evaluated the prognostic impact of EGFR gene status by fluorescent in situ hybridization (FISH), EGFR coding mutations by Sanger and next-generation sequencing, relative EGFR messenger RNA (mRNA) levels by qPCR (upper quartile) and EGFR and p53 protein expression by immunohistochemistry (IHC), in 352 centrally-assessed tumors from an equal number of TNBC patients...
May 2017: Cancer Genomics & Proteomics
https://www.readbyqxmd.com/read/28286614/is-there-any-concordance-between-of-ihc-with-fish-in-her2-positive-breast-cancer-patients
#4
Mehrdad Payandeh, Masoud Sadeghi, Edris Sadeghi, Alireza Janbakhsh
Background: In developed or developing countries, the most common cancer in women is breast cancer with a pick in 40-50 years in Asia. Herein, we compared the association between IHC with FISH in HER2-positive breast cancer patients and affection of trastuzumab on disease free survival and overall survival (OS). Subjects and Methods: Immunohistochemical (IHC) analysis of hormone receptors and HER2 was performed in 133 patients with breast cancer between 2003 and 2014. Patients were selected for Herceptin adjuvant treatment, according to IHC 3+ or FISH+...
January 1, 2017: International Journal of Hematology-oncology and Stem Cell Research
https://www.readbyqxmd.com/read/28027945/next-generation-assessment-of-human-epidermal-growth-factor-receptor-2-erbb2-amplification-status-clinical-validation-in-the-context-of-a-hybrid-capture-based-comprehensive-solid-tumor-genomic-profiling-assay
#5
Dara S Ross, Ahmet Zehir, Donavan T Cheng, Ryma Benayed, Khedoudja Nafa, Jaclyn F Hechtman, Yelena Y Janjigian, Britta Weigelt, Pedram Razavi, David M Hyman, José Baselga, Michael F Berger, Marc Ladanyi, Maria E Arcila
Establishing ERBB2 [human epidermal growth factor receptor 2 (HER2)] amplification status in breast and gastric carcinomas is essential to treatment selection. Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) constitute the current standard for assessment. With further advancements in genomic medicine, new clinically relevant biomarkers are rapidly emerging and options for targeted therapy are increasing in patients with advanced disease, driving the need for comprehensive molecular profiling...
March 2017: Journal of Molecular Diagnostics: JMD
https://www.readbyqxmd.com/read/27993329/an-mrna-gene-expression-based-signature-to-identify-fgfr1-amplified-estrogen-receptor-positive-breast-tumors
#6
Jingqin Luo, Shuzhen Liu, Samuel Leung, Alejandro A Gru, Yu Tao, Jeremy Hoog, Julie Ho, Sherri R Davies, D Craig Allred, Andrea L Salavaggione, Jacqueline Snider, Elaine R Mardis, Torsten O Nielsen, Matthew J Ellis
Fibroblast growth factor receptor 1 (FGFR1) amplification drives poor prognosis and is an emerging therapeutic target. We sought to construct a multigene mRNA expression signature to efficiently identify FGFR1-amplified estrogen receptor-positive (ER(+)) breast tumors. Five independent breast tumor series were analyzed. Genes discriminative for FGFR1 amplification were screened transcriptome-wide by receiver operating characteristic analyses. The METABRIC series was leveraged to construct/evaluate four approaches to signature composition...
January 2017: Journal of Molecular Diagnostics: JMD
https://www.readbyqxmd.com/read/27895501/a-fish-based-method-for-assessment-of-her-2-amplification-status-in-breast-cancer-circulating-tumor-cells-following-cellsearch-isolation
#7
Henrik Frithiof, Kristina Aaltonen, Lisa Rydén
INTRODUCTION: Amplification of the HER-2/neu (HER-2) proto-oncogene occurs in 10%-15% of primary breast cancer, leading to an activated HER-2 receptor, augmenting growth of cancer cells. Tumor classification is determined in primary tumor tissue and metastatic biopsies. However, malignant cells tend to alter their phenotype during disease progression. Circulating tumor cell (CTC) analysis may serve as an alternative to repeated biopsies. The Food and Drug Administration-approved CellSearch system allows determination of the HER-2 protein, but not of the HER-2 gene...
2016: OncoTargets and Therapy
https://www.readbyqxmd.com/read/27893937/prognostic-significance-of-equivocal-human-epidermal-growth-factor-receptor-2-results-and-clinical-utility-of-alternative-chromosome-17-genes-in-patients-with-invasive-breast-cancer-a-cohort-study
#8
Nour Sneige, Kenneth R Hess, Asha S Multani, Yun Gong, Nuhad K Ibrahim
BACKGROUND: The 2013 testing guidelines for determining the human epidermal growth factor receptor 2 (HER2) status include new cutoff points for the HER2/chromosome enumeration probe 17 (CEP17) ratio and the average HER2 copy number per cell, and they recommend using a reflex test with alternative chromosome 17 probes (Ch17Ps) to resolve equivocal HER2 results. This study sought to determine the clinical utility of alternative Ch17Ps in equivocal cases and the effects of equivocal results and/or a change in the HER2 status on patients' outcomes...
April 1, 2017: Cancer
https://www.readbyqxmd.com/read/27864894/maternal-dietary-intake-in-pregnancy-and-lactation-and-allergic-disease-outcomes-in-offspring
#9
REVIEW
Carina Venter, Kari R Brown, Kate Maslin, Debra J Palmer
As the prevalence of allergic disease dramatically rises worldwide, prevention strategies are increasingly being considered. Given the potential modulatory effect of nutritional factors on disease, altering maternal diet during pregnancy and/or lactation has been considered in preventing allergic disease in offspring. Although there are a number of observational studies that have examined possible associations between maternal diet and allergic outcomes in offspring, interventional trials are limited. Furthermore, there is a paucity of studies that have prospectively studied maternal dietary intake as well as measuring maternal and infant biologic samples (blood, urine, breast milk) and their relation to allergic outcomes in infants...
March 2017: Pediatric Allergy and Immunology
https://www.readbyqxmd.com/read/27861897/genome-evolution-in-ductal-carcinoma-in-situ-invasion-of-the-clones
#10
REVIEW
Anna K Casasent, Mary Edgerton, Nicholas E Navin
Ductal carcinoma in situ (DCIS) is the most frequently diagnosed early-stage breast cancer. Only a subset of patients progress to invasive ductal carcinoma (IDC), and this presents a formidable clinical challenge for determining which patients to treat aggressively and which patients to monitor without therapeutic intervention. Understanding the molecular and genomic basis of invasion has been difficult to study in DCIS cancers due to several technical obstacles, including low tumour cellularity, lack of fresh-frozen tissues, and intratumour heterogeneity...
January 2017: Journal of Pathology
https://www.readbyqxmd.com/read/27835607/p16-overexpression-and-9p21-deletion-are-linked-to-unfavorable-tumor-phenotype-in-breast-cancer
#11
Patrick Lebok, Magdalena Roming, Martina Kluth, Christina Koop, Cansu Özden, Berivan Taskin, Khakan Hussein, Annette Lebeau, Isabell Witzel, Linn Wölber, Stefan Geist, Peter Paluchowski, Christian Wilke, Uwe Heilenkötter, Volkmar Müller, Barbara Schmalfeldt, Ronald Simon, Guido Sauter, Luigi Terracciano, Rainer Horst Krech, Albert von der Assen, Eike Burandt
Overexpression of the p16 tumor suppressor, but also deletion of its gene locus 9p21, is linked to unfavorable tumor phenotype and poor prognosis in breast cancer. To better understand these contradictory observations, and to clarify the prognostic impact of p16 expression and 9p21 deletion, a tissue microarray (TMA) with 2,197 breast cancers was analyzed by fluorescence in-situ hybridization and immunohistochemistry (FISH) for 9p21 deletion and p16 expression. p16 immunostaining was weak in 25.6%, moderate in 7...
December 6, 2016: Oncotarget
https://www.readbyqxmd.com/read/27785012/docosahexaenoic-acid-liposomes-for-targeting-chronic-inflammatory-diseases-and-cancer-an-in-vitro-assessment
#12
Amr Alaarg, Nan Yeun Jordan, Johan Jf Verhoef, Josbert M Metselaar, Gert Storm, Robbert J Kok
Inflammation, oxidative stress, and uncontrolled cell proliferation are common key features of chronic inflammatory diseases, such as atherosclerosis and cancer. ω3 polyunsaturated fatty acids (PUFAs; also known as omega3 fatty acids or fish oil) have beneficial effects against inflammation upon dietary consumption. However, these effects cannot be fully exploited unless diets are enriched with high concentrations of fish oil supplements over long periods of time. Here, a nanomedicine-based approach is presented for delivering effective levels of PUFAs to inflammatory cells...
2016: International Journal of Nanomedicine
https://www.readbyqxmd.com/read/27770345/chemosensitivity-and-endocrine-sensitivity-in-clinical-luminal-breast-cancer-patients-in-the-prospective-neoadjuvant-breast-registry-symphony-trial-nbrst-predicted-by-molecular-subtyping
#13
Pat Whitworth, Peter Beitsch, Angela Mislowsky, James V Pellicane, Charles Nash, Mary Murray, Laura A Lee, Carrie L Dul, Michael Rotkis, Paul Baron, Lisette Stork-Sloots, Femke A de Snoo, Jennifer Beatty
PURPOSE: Hormone receptor-positive (HR+) tumors have heterogeneous biology and present a challenge for determining optimal treatment. In the Neoadjuvant Breast Registry Symphony Trial (NBRST) patients were classified according to MammaPrint/BluePrint subtyping to provide insight into the response to neoadjuvant endocrine therapy (NET) or neoadjuvant chemotherapy (NCT). OBJECTIVE: The purpose of this predefined substudy was to compare MammaPrint/BluePrint with conventional 'clinical' immunohistochemistry/fluorescence in situ hybridization (IHC/FISH) subtyping in 'clinical luminal' [HR+/human epidermal growth factor receptor 2-negative (HER2-)] breast cancer patients to predict treatment sensitivity...
March 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/27748278/evaluation-of-her2-neu-oncoprotein-in-serum-tissue-samples-of-women-with-breast-cancer
#14
Shailaja Shukla, Bhawana Komal Singh, Om Prakash Pathania, Manjula Jain
BACKGROUND & OBJECTIVES: The proto-oncogene HER2/neu has been extensively studied in breast cancer patients. Serum levels of HER2/neu by ELISA in breast cancer patients were compared with tissue HER2/neu expression and with other clinicopathological parameters with the aim to investigate whether the serum assay could replace the established tests (IHC/FISH) for HER-2 status. METHODS: Blood and Tru-cut biopsy samples were collected for determining HER2/neu status in 64 breast cancer patients...
May 2016: Indian Journal of Medical Research
https://www.readbyqxmd.com/read/27739521/label-free-enumeration-collection-and-downstream-cytological-and-cytogenetic-analysis-of-circulating-tumor-cells
#15
Manjima Dhar, Edward Pao, Corinne Renier, Derek E Go, James Che, Rosita Montoya, Rachel Conrad, Melissa Matsumoto, Kyra Heirich, Melanie Triboulet, Jianyu Rao, Stefanie S Jeffrey, Edward B Garon, Jonathan Goldman, Nagesh P Rao, Rajan Kulkarni, Elodie Sollier-Christen, Dino Di Carlo
Circulating tumor cells (CTCs) have a great potential as indicators of metastatic disease that may help physicians improve cancer prognostication, treatment and patient outcomes. Heterogeneous marker expression as well as the complexity of current antibody-based isolation and analysis systems highlights the need for alternative methods. In this work, we use a microfluidic Vortex device that can selectively isolate potential tumor cells from blood independent of cell surface expression. This system was adapted to interface with three protein-marker-free analysis techniques: (i) an in-flow automated image processing system to enumerate cells released, (ii) cytological analysis using Papanicolaou (Pap) staining and (iii) fluorescence in situ hybridization (FISH) targeting the ALK rearrangement...
October 14, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27633145/gata3-expression-in-primary-vulvar-paget-disease-a-potential-pitfall-leading-to-misdiagnosis-of-pagetoid-urothelial-intraepithelial-neoplasia
#16
Diogo Morbeck, Aline C Tregnago, Glauco Baiocchi Netto, Carlos Sacomani, Patricia M Peresi, Cynthia T Osório, Luciana Schutz, Stephania M Bezerra, Louise de Brot, Isabela W Cunha
AIMS: GATA3 has been reported as a specific urothelial marker among organs in the pelvic region, and has been classified as highly sensitive and specific for urothelial and breast carcinomas. Our aim was to verify GATA3 expression in extramammary Paget disease, and to determine whether it can be use to differentiate primary vulvar Paget disease from pagetoid urothelial intraepithelial neoplasia (PUIN). We also analysed HER2 protein expression and HER2 gene amplification and their roles as prognostic factors in extramammary Paget disease...
February 2017: Histopathology
https://www.readbyqxmd.com/read/27632289/use-of-a-multiplexed-immunoassay-pro-onc-assay-to-detect-her2-abnormalities-in-circulating-tumor-cells-of-women-with-her2-negative-metastatic-breast-cancer-lack-of-response-to-her2-targeted-therapy
#17
John D Hainsworth, Patrick B Murphy, Jose R Alemar, Brooke R Daniel, Robyn R Young, Denise A Yardley
PURPOSE: Determination of HER2 status by testing circulating tumor cells (CTCs), compared to sampling tumor biopsies, may improve patient management by allowing ongoing assessment of HER2 status during the disease course. The PRO Onc assay (Prometheus Laboratories; San Diego, CA) is a multiplexed immunoassay that measures the expression and activation of HER2 in CTCs. In this study, we screened patients with metastatic HER2-negative breast cancer with the PRO Onc assay; patients with HER2 overexpression or activation received a trial of HER2-targeted therapy...
November 2016: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/27631512/proposal-of-a-provisional-classification-of-sebaceous-carcinoma-based-on-hormone-receptor-expression-and-her2-status
#18
Hee Young Na, Ji-Young Choe, Seon Ah Shin, Ho-Kyung Choung, Sohee Oh, Jin-Haeng Chung, Mira Park, Ji Eun Kim
Despite recent progress in comprehensive genetic analysis, little is known about the molecular pathogenesis of sebaceous carcinoma. On the basis of the ontogenic proximity of sebaceous and mammary glands, we designed an intrinsic classification for sebaceous carcinoma adapted from that of breast cancer and evaluated its clinical significance. We investigated 42 cases of sebaceous carcinoma, including 32 ocular and 10 extraocular cases. Immunohistochemical analyses for estrogen receptor (ER), progesterone receptor (PR), androgen receptor (AR), HER2, Ki67, and CK5/6 and fluorescence in situ hybridization for the HER2 gene were performed...
December 2016: American Journal of Surgical Pathology
https://www.readbyqxmd.com/read/27626701/cdcp1-is-a-novel-marker-of-the-most-aggressive-human-triple-negative-breast-cancers
#19
Federica Turdo, Francesca Bianchi, Patrizia Gasparini, Marco Sandri, Marianna Sasso, Loris De Cecco, Luca Forte, Patrizia Casalini, Piera Aiello, Lucia Sfondrini, Roberto Agresti, Maria Luisa Carcangiu, Ilaria Plantamura, Gabriella Sozzi, Elda Tagliabue, Manuela Campiglio
CDCP1, a transmembrane noncatalytic receptor, the expression of which has been associated with a poor prognosis in certain epithelial cancers, was found to be expressed in highly aggressive triple-negative breast cancer (TNBC) cell models, in which it promoted aggressive activities-ie, migration, invasion, anchorage-independent tumor growth, and the formation of vascular-like structures in vitro. By immunohistochemical (IHC) analysis of 100 human TNBC specimens, CDCP1 was overexpressed in 57% of samples, 38% of which exhibited a gain in CDCP1 copy number by fluorescence in situ hybridization (FISH)...
October 25, 2016: Oncotarget
https://www.readbyqxmd.com/read/27589688/primary-analysis-of-a-prospective-randomized-single-blinded-phase-ii-trial-evaluating-the-her2-peptide-gp2-vaccine-in-breast-cancer-patients-to-prevent-recurrence
#20
Elizabeth A Mittendorf, Alexandros Ardavanis, Jennifer K Litton, Nathan M Shumway, Diane F Hale, James L Murray, Sonia A Perez, Sathibalan Ponniah, Constantin N Baxevanis, Michael Papamichail, George E Peoples
GP2 is a HER2-derived, HLA-A2+ restricted peptide. Phase I studies showed GP2 administered with GM-CSF to be safe and immunogenic. Here we report the primary analysis of a prospective, randomized, multicenter phase II adjuvant trial conducted to determine the vaccine's efficacy. The trial enrolled HLA-A2+, clinically disease-free, node-positive and high-risk node-negative breast cancer patients with tumors expressing HER2 (immunohistochemistry[IHC] 1+-3+). Patients were randomized to GP2+GM-CSF versus GM-CSF alone...
October 4, 2016: Oncotarget
keyword
keyword
106355
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"